Assessment of Quality of Life in a Sample of Iraqi Patients with Psoriasis.

Abdulridha, Sarah H; Kadhim, Dheyaa Jasim; Razzak, Sarmad A. Abdul

doi:10.31351/vol29iss2pp161-168

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proteins of the S100A family mediate inflammatory reactions by acting on a variety of immune and non-immune cells, including monocytes, neutrophils, endothelial cells, keratinocytes, and epithelial cells, to produce proinflammatory cytokines . Furthermore, the Imiquimod-based psoriasis murine model revealed a strong link between the role of NK cells in the pathogenesis of autoimmune diseases like psoriasis and paquinimod, a drug that has been shown to modify NKT-II cells and reduces the priming of proinflam-matory effector CD4 (+) T cells, CD115+ Ly6Chi monocytes, and CD11b+ F4/80+ CD206+ macrophage [19][20] .…”

Section: Discussionmentioning

confidence: 99%

Immune-protective effect of topical paquinimod administration against imiquimod-induced psoriasis-like inflammation in mice

Khaleel

Zalzala

Rashid

2023

View full text Add to dashboard Cite

Psoriasis is a chronic, inflammatory condition that primarily affects the skin, hair, and joints and is associated with significant humanistic and economic consequences. This work induced psoriasis in mice using an imiquimod 5% cream, an immune response modifier that can cause psoriasis-like skin inflammation when given orally. Paquinimod is prepared as an ointment and has been topically given to mice before imiquimod application. In this study, albino mice were allocated into five groups and treated as follows: the control group received only a daily application of cream based on shaved back (62.5mg/2cm) with a daily topical dose of ointment for 14 consecutive days with the oral vehicle. The Imiquimod group received a daily topical dose of vehicle one hour before imiquimod 5% application on shaved back (62.5mg/2cm) for 14 consecutive days. The paquinimod-treated group received daily topical doses of paquinimod one hour before imiquimod 5% application on shaved back (62.5mg/2cm) for 14 consecutive days. Clobetasol -treated group received a daily topical dose of clobetasol ointment (62.5mg/2cm) one hour before imiquimod 5% application on shaved back (62.5mg/2cm) for 14 consecutive days. Paquinimod, the only group that received a daily oral dose of paquinimod for 14 consecutive days. The current study found that the administration of paquinimod ointment resulted in a significant decline in TNF-α, IL-23, IL17 level, reduced psoriasis area and severity index, spleen index, skin thickness, and gene expression of TNF-α, Nf-KB, IL-1B, IL-17in the (Paquinimod ointment+imiquimod) group substantially more than that in the (vehicle ointment+imiquimod) groups. In conclusion, paquinimod has a powerful ameliorating effect that can reduce the IMQ-induced psoriasis-like inflammation in a mouse model. As a result, we have every reason to believe that paquinimod will be utilized to treat psoriasis. Keywords: Psoriasis; Paquinimod; Imiquimod; IL-23; IL-17; TNF-α.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-protective effect of topical paquinimod administration against imiquimod-induced psoriasis-like inflammation in mice

Khaleel

Zalzala

Rashid

2023

View full text Add to dashboard Cite

show abstract

Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics

Al-Jalehawi,

Mohammed

2024

Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed.

View full text Add to dashboard Cite

This comprehensive review examines the efficacy and safety of tumor necrosis factor-alpha (TNF-α) inhibitors in treating various autoimmune diseases, and focuses on their application in Iraqi patients. Elevated TNF-α levels are linked to autoimmune disorders, leading to the development of anti-TNF-α therapies such as infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab, which have gained FDA approval for conditions like psoriasis, in¬flammatory bowel disease, ankylosing spondylitis, and rheumatoid arthritis. While these therapies demonstrate sig¬nificant therapeutic benefits, including improved quality of life and disease management, they also carry risks, such as increased susceptibility to infections and potential malignancies. The review highlights the variable patient re¬sponses to TNF-α inhibitors, influenced by pharmacokinetic and pharmacodynamic factors as well as genetic varia¬tions. The rise of anti-drug antibodies and inadequate drug concentrations are common challenges observed, empha¬sizing the need for therapeutic drug monitoring. Safety profiles of TNF-α inhibitors are generally favorable, but adverse effects (including infections and infusion reactions) have been reported. Genetic factors, such as polymorphisms in the TNF-α gene, may also play a role in the treatment responsiveness and adverse effects, suggesting the potential for personalized medicine approaches. While TNF-α inhibitors effectively manage autoimmune diseases in Iraqi pa¬tients, further research is warranted in order to optimize treatment strategies, assess long-term safety, and explore genetic influences on therapy outcomes. The findings underscore the importance of individualized treatment plans so as to enhance the efficacy and minimize the risks associated with these biologic therapies.

show abstract

Assessment of Quality of Life in a Sample of Iraqi Patients with Psoriasis.

Cited by 2 publications

References 30 publications

Immune-protective effect of topical paquinimod administration against imiquimod-induced psoriasis-like inflammation in mice

Immune-protective effect of topical paquinimod administration against imiquimod-induced psoriasis-like inflammation in mice

Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics

Contact Info

Product

Resources

About